Advantages:

Repeated intravitreal injections of bevacizumab (IVB) are more efficacious than repeated intravitreal injections of triamcinolone (IVT) in the treatment of macular edema in eyes with acute central retinal vein occlusion (CRVO).

Methods:

In a randomized clinical trial, 110 eyes with recent onset (less than 12 weeks) CRVO were included. Participants were randomly assigned to two treatment groups: IVB group (56 eyes), patients who received 3 monthly injections of 1.25 mg of IVB, and IVT group (54 eyes), patients who received 2 injections of 2 mg IVT two months apart. Patients were examined at 1, 2, 3, 4, and 6 months after enrollment. Main Outcome Measure was change in best-corrected visual acuity (BCVA) at 6 months. Secondary outcome measures were central macular thickness (CMT) and intraocular pressure (IOP) changes at month 6.

Effectiveness / Safety:

Mean BCVA improved significantly up to 6 months in both groups from 0.87 ± 0.49 to 0.41 ± 0.35 logMAR (logarithm of minimum angle of resolution) in the IVB group and from 0.81 ± 0.45 to 0.62 ± 0.48 logMAR in the IVT group.